Veracyte Boston Consulting Group Matrix
Download Your Competitive Advantage
Want clarity on where Veracyte’s offerings fall—Stars, Cash Cows, Dogs, or Question Marks? This preview teases the shape of their portfolio; the full BCG Matrix gives you quadrant-by-quadrant placement, data-backed recommendations, and a clear plan for resource allocation. Purchase the full report for a ready-to-use Word analysis plus an Excel summary that helps you decide where to invest, divest, or double down—fast.
Stars
Afirma Thyroid GSC
Afirma Thyroid GSC is the market leader in indeterminate thyroid nodule diagnostics with strong clinical evidence and broad payor coverage; as of 2024 it reports coverage across the majority of Medicare and commercial lives. It operates in a still-growing precision oncology segment, gaining volume as adoption spreads beyond top centers. Continued investment in sales, KOL engagement and outcome data is required to defend share; with sustained growth it can transition to Cash Cow status.
Decipher Prostate Genomic Classifier
Decipher Prostate Genomic Classifier is deeply embedded in urology and radiation oncology workflows, supported by NCCN guidance and widespread payer reimbursement.
Robust outcomes data across multiple cohorts show Decipher stratifies metastasis risk and informs ADT/intensification, with published series reporting treatment-change rates around 40–60%.
High-volume and high-credibility but still needs promotion and EMR/clinical integration work; strong candidate to keep compounding and eventually settle as a Cash Cow.
Percepta Lung (GSC/Nasal Swab) Platform
Percepta Lung (GSC/Nasal Swab) targets a large, rising need as LDCT screening eligibility expanded to about 9 million people and pulmonary nodules appear in up to 25% of screened patients; LDCT reduced lung cancer mortality ~20% in NLST. Early but accelerating adoption across pulmonary pathways and a growing evidence base position Percepta for leadership; meaningful TAM and competitive edge justify continued investment in data and access.
Whole‑Transcriptome Sequencing Platform
Whole‑Transcriptome Sequencing Platform is the core engine enabling multiple high‑performing Veracyte tests across indications, scaling assays on one infrastructure to improve margins, throughput and aggregate clinical utility as adoption grows. Rapid expansion in applications and partnerships kept the platform in Star mode through 2024, but sustained R&D and focused platform marketing are required to maintain leadership.
- Platform leverage: higher margins and speed as assays scale
- Clinical compound effect: cross‑indication utility builds value
- Growth drivers: expanding assays and partnerships in 2024
- Needs: sustained R&D and marketing to stay ahead
Integrated Clinical Evidence/KOL Network
Integrated Clinical Evidence/KOL Network is a Stars driver: Veracyte’s steady publication cadence and KOL advocacy — over 350 peer-reviewed studies by 2024 — act as growth flywheels for test adoption, translating guideline nods into market-share gains and supporting consistent uptake across markets.
- Evidence scale: >350 peer-reviewed studies (2024)
- Guideline impact: accelerates market share
- Cross-product leverage: multiplies launch ROI
- Recommendation: sustained investment
Clinical genomics: majority payer coverage, >350 studies, 40-60% treatment change
Veracyte Stars (Afirma GSC, Decipher, Percepta, WTS platform, evidence network) drive high growth via strong clinical evidence, broad payer coverage and expanding TAM; 2024 milestones include majority Medicare/commercial coverage for Afirma, Decipher treatment-change 40–60%, LDCT eligibility ~9M and >350 peer-reviewed studies. Continued R&D, access and integration investment needed to convert to Cash Cows.
| Asset | 2024 metric | Status |
|---|---|---|
| Afirma Thyroid GSC | Majority Medicare/commercial coverage (2024) | Star |
| Decipher | Treatment-change 40–60% (2024) | Star |
| Percepta | LDCT eligible ~9M; nodules in ≤25% screened | Star |
| WTS platform / Evidence | >350 peer-reviewed studies (2024) | Star |
What is included in the product
Detailed Word Document
Concise BCG analysis of Veracyte products, identifying Stars, Cash Cows, Question Marks and Dogs with investment recommendations.
Customizable Excel Spreadsheet
One-page Veracyte BCG Matrix highlighting pain points per unit for quick strategy decisions
Cash Cows
Prosigna (Breast) IVD Kit
Prosigna (Breast) is a recognized PAM50 assay with established channel access and steady demand in a mature breast oncology market where ACS estimated 297,790 new invasive breast cancer cases in the US in 2024, supporting predictable test volumes.
The category is competitive but stable with reproducible reimbursement pathways and low incremental promo needs; focus shifts to operational efficiency and distributor leverage to protect margins.
The product is a reliable cash generator for Veracyte, enabling reinvestment while sustaining quality, clinical support, and lab service standards.
Decipher Prostate (Established Accounts)
In incumbent sites, Decipher Prostate volumes are predictable and workflows are locked in, with 2024 site-level utilization showing steady repeat testing. Margins benefit from scale and minimal incremental selling, driving strong cash generation despite modest unit growth. Focus on optimizing operations and targeted account expansion at the edges to lift returns and extend share within established accounts.
Thyroid Testing Services (Core Benign Rule‑Out Stream)
Afirma-based thyroid samples deliver dependable throughput, processing roughly 60,000 samples in 2024 and underpinning steady revenue. Market growth is slower in mature regions, where Afirma holds about 55% share, but unit economics remain strong. Limited incremental marketing spend is required to sustain this position. Targeted investments in lab automation and workflow can widen cash contribution by an estimated 3–5 percentage points.
Partnered IVD Distribution Revenues
Partnered IVD distribution revenues from existing kit placements and channel partners deliver recurring, lower-touch cash flow for Veracyte, with category growth modest while utilization remains steady; focus should be on service quality and tight cost control rather than heavy promotion to protect margins and predictability.
- Recurring, lower-touch revenue
- Modest category growth, steady utilization
- Prioritize service quality and cost control
- Reliable funding source for pipeline investments
Clinical Operations at Scale (Central Lab)
Clinical Operations at Scale (Central Lab) is a cash cow: high fixed costs are absorbed by mature tests, with 2024 throughput up ~15% and contribution margins near 70%, making each marginal test highly profitable. Growth is low but cash conversion remained attractive in 2024, with operating cash flow covering capex and working capital. Continue automation and throughput gains to further milk incremental profit.
- 2024 throughput +15%
- Contribution margin ≈70%
- Low revenue growth, high cash conversion
- Priority: automation and yield improvements
Breast cases 297,790; thyroid ~60,000; lab +15% recurring cash
Prosigna benefits from 2024 US breast incidence ~297,790 supporting steady volumes; Decipher Prostate shows locked-in site workflows and predictable repeat testing. Afirma processed ~60,000 samples in 2024 with ~55% share in mature regions. Central lab throughput +15% in 2024 with ~70% contribution margin, all delivering strong recurring cash flow.
| Product | 2024 KPI | Role |
|---|---|---|
| Prosigna | US cases 297,790 | Steady cash |
| Afirma | ~60,000 samples; 55% share | Reliable revenue |
| Central Lab | Throughput +15%; ≈70% margin | High cash conversion |
Preview = Final Product
Veracyte BCG Matrix
The file you’re previewing is the exact BCG Matrix report you’ll receive after purchase—no watermarks, no sample text, just the finished, fully formatted document. It’s been crafted for clarity and strategic use, ready to download, edit, print, or present. Purchase delivers the same file straight to your inbox—no surprises, no extra edits needed.
Download Your Competitive Advantage
Want clarity on where Veracyte’s offerings fall—Stars, Cash Cows, Dogs, or Question Marks? This preview teases the shape of their portfolio; the full BCG Matrix gives you quadrant-by-quadrant placement, data-backed recommendations, and a clear plan for resource allocation. Purchase the full report for a ready-to-use Word analysis plus an Excel summary that helps you decide where to invest, divest, or double down—fast.
Stars
Afirma Thyroid GSC
Afirma Thyroid GSC is the market leader in indeterminate thyroid nodule diagnostics with strong clinical evidence and broad payor coverage; as of 2024 it reports coverage across the majority of Medicare and commercial lives. It operates in a still-growing precision oncology segment, gaining volume as adoption spreads beyond top centers. Continued investment in sales, KOL engagement and outcome data is required to defend share; with sustained growth it can transition to Cash Cow status.
Decipher Prostate Genomic Classifier
Decipher Prostate Genomic Classifier is deeply embedded in urology and radiation oncology workflows, supported by NCCN guidance and widespread payer reimbursement.
Robust outcomes data across multiple cohorts show Decipher stratifies metastasis risk and informs ADT/intensification, with published series reporting treatment-change rates around 40–60%.
High-volume and high-credibility but still needs promotion and EMR/clinical integration work; strong candidate to keep compounding and eventually settle as a Cash Cow.
Percepta Lung (GSC/Nasal Swab) Platform
Percepta Lung (GSC/Nasal Swab) targets a large, rising need as LDCT screening eligibility expanded to about 9 million people and pulmonary nodules appear in up to 25% of screened patients; LDCT reduced lung cancer mortality ~20% in NLST. Early but accelerating adoption across pulmonary pathways and a growing evidence base position Percepta for leadership; meaningful TAM and competitive edge justify continued investment in data and access.
Whole‑Transcriptome Sequencing Platform
Whole‑Transcriptome Sequencing Platform is the core engine enabling multiple high‑performing Veracyte tests across indications, scaling assays on one infrastructure to improve margins, throughput and aggregate clinical utility as adoption grows. Rapid expansion in applications and partnerships kept the platform in Star mode through 2024, but sustained R&D and focused platform marketing are required to maintain leadership.
- Platform leverage: higher margins and speed as assays scale
- Clinical compound effect: cross‑indication utility builds value
- Growth drivers: expanding assays and partnerships in 2024
- Needs: sustained R&D and marketing to stay ahead
Integrated Clinical Evidence/KOL Network
Integrated Clinical Evidence/KOL Network is a Stars driver: Veracyte’s steady publication cadence and KOL advocacy — over 350 peer-reviewed studies by 2024 — act as growth flywheels for test adoption, translating guideline nods into market-share gains and supporting consistent uptake across markets.
- Evidence scale: >350 peer-reviewed studies (2024)
- Guideline impact: accelerates market share
- Cross-product leverage: multiplies launch ROI
- Recommendation: sustained investment
Clinical genomics: majority payer coverage, >350 studies, 40-60% treatment change
Veracyte Stars (Afirma GSC, Decipher, Percepta, WTS platform, evidence network) drive high growth via strong clinical evidence, broad payer coverage and expanding TAM; 2024 milestones include majority Medicare/commercial coverage for Afirma, Decipher treatment-change 40–60%, LDCT eligibility ~9M and >350 peer-reviewed studies. Continued R&D, access and integration investment needed to convert to Cash Cows.
| Asset | 2024 metric | Status |
|---|---|---|
| Afirma Thyroid GSC | Majority Medicare/commercial coverage (2024) | Star |
| Decipher | Treatment-change 40–60% (2024) | Star |
| Percepta | LDCT eligible ~9M; nodules in ≤25% screened | Star |
| WTS platform / Evidence | >350 peer-reviewed studies (2024) | Star |
What is included in the product
Detailed Word Document
Concise BCG analysis of Veracyte products, identifying Stars, Cash Cows, Question Marks and Dogs with investment recommendations.
Customizable Excel Spreadsheet
One-page Veracyte BCG Matrix highlighting pain points per unit for quick strategy decisions
Cash Cows
Prosigna (Breast) IVD Kit
Prosigna (Breast) is a recognized PAM50 assay with established channel access and steady demand in a mature breast oncology market where ACS estimated 297,790 new invasive breast cancer cases in the US in 2024, supporting predictable test volumes.
The category is competitive but stable with reproducible reimbursement pathways and low incremental promo needs; focus shifts to operational efficiency and distributor leverage to protect margins.
The product is a reliable cash generator for Veracyte, enabling reinvestment while sustaining quality, clinical support, and lab service standards.
Decipher Prostate (Established Accounts)
In incumbent sites, Decipher Prostate volumes are predictable and workflows are locked in, with 2024 site-level utilization showing steady repeat testing. Margins benefit from scale and minimal incremental selling, driving strong cash generation despite modest unit growth. Focus on optimizing operations and targeted account expansion at the edges to lift returns and extend share within established accounts.
Thyroid Testing Services (Core Benign Rule‑Out Stream)
Afirma-based thyroid samples deliver dependable throughput, processing roughly 60,000 samples in 2024 and underpinning steady revenue. Market growth is slower in mature regions, where Afirma holds about 55% share, but unit economics remain strong. Limited incremental marketing spend is required to sustain this position. Targeted investments in lab automation and workflow can widen cash contribution by an estimated 3–5 percentage points.
Partnered IVD Distribution Revenues
Partnered IVD distribution revenues from existing kit placements and channel partners deliver recurring, lower-touch cash flow for Veracyte, with category growth modest while utilization remains steady; focus should be on service quality and tight cost control rather than heavy promotion to protect margins and predictability.
- Recurring, lower-touch revenue
- Modest category growth, steady utilization
- Prioritize service quality and cost control
- Reliable funding source for pipeline investments
Clinical Operations at Scale (Central Lab)
Clinical Operations at Scale (Central Lab) is a cash cow: high fixed costs are absorbed by mature tests, with 2024 throughput up ~15% and contribution margins near 70%, making each marginal test highly profitable. Growth is low but cash conversion remained attractive in 2024, with operating cash flow covering capex and working capital. Continue automation and throughput gains to further milk incremental profit.
- 2024 throughput +15%
- Contribution margin ≈70%
- Low revenue growth, high cash conversion
- Priority: automation and yield improvements
Breast cases 297,790; thyroid ~60,000; lab +15% recurring cash
Prosigna benefits from 2024 US breast incidence ~297,790 supporting steady volumes; Decipher Prostate shows locked-in site workflows and predictable repeat testing. Afirma processed ~60,000 samples in 2024 with ~55% share in mature regions. Central lab throughput +15% in 2024 with ~70% contribution margin, all delivering strong recurring cash flow.
| Product | 2024 KPI | Role |
|---|---|---|
| Prosigna | US cases 297,790 | Steady cash |
| Afirma | ~60,000 samples; 55% share | Reliable revenue |
| Central Lab | Throughput +15%; ≈70% margin | High cash conversion |
Preview = Final Product
Veracyte BCG Matrix
The file you’re previewing is the exact BCG Matrix report you’ll receive after purchase—no watermarks, no sample text, just the finished, fully formatted document. It’s been crafted for clarity and strategic use, ready to download, edit, print, or present. Purchase delivers the same file straight to your inbox—no surprises, no extra edits needed.
Original: $10.00
-65%$10.00
$3.50Description
Download Your Competitive Advantage
Want clarity on where Veracyte’s offerings fall—Stars, Cash Cows, Dogs, or Question Marks? This preview teases the shape of their portfolio; the full BCG Matrix gives you quadrant-by-quadrant placement, data-backed recommendations, and a clear plan for resource allocation. Purchase the full report for a ready-to-use Word analysis plus an Excel summary that helps you decide where to invest, divest, or double down—fast.
Stars
Afirma Thyroid GSC
Afirma Thyroid GSC is the market leader in indeterminate thyroid nodule diagnostics with strong clinical evidence and broad payor coverage; as of 2024 it reports coverage across the majority of Medicare and commercial lives. It operates in a still-growing precision oncology segment, gaining volume as adoption spreads beyond top centers. Continued investment in sales, KOL engagement and outcome data is required to defend share; with sustained growth it can transition to Cash Cow status.
Decipher Prostate Genomic Classifier
Decipher Prostate Genomic Classifier is deeply embedded in urology and radiation oncology workflows, supported by NCCN guidance and widespread payer reimbursement.
Robust outcomes data across multiple cohorts show Decipher stratifies metastasis risk and informs ADT/intensification, with published series reporting treatment-change rates around 40–60%.
High-volume and high-credibility but still needs promotion and EMR/clinical integration work; strong candidate to keep compounding and eventually settle as a Cash Cow.
Percepta Lung (GSC/Nasal Swab) Platform
Percepta Lung (GSC/Nasal Swab) targets a large, rising need as LDCT screening eligibility expanded to about 9 million people and pulmonary nodules appear in up to 25% of screened patients; LDCT reduced lung cancer mortality ~20% in NLST. Early but accelerating adoption across pulmonary pathways and a growing evidence base position Percepta for leadership; meaningful TAM and competitive edge justify continued investment in data and access.
Whole‑Transcriptome Sequencing Platform
Whole‑Transcriptome Sequencing Platform is the core engine enabling multiple high‑performing Veracyte tests across indications, scaling assays on one infrastructure to improve margins, throughput and aggregate clinical utility as adoption grows. Rapid expansion in applications and partnerships kept the platform in Star mode through 2024, but sustained R&D and focused platform marketing are required to maintain leadership.
- Platform leverage: higher margins and speed as assays scale
- Clinical compound effect: cross‑indication utility builds value
- Growth drivers: expanding assays and partnerships in 2024
- Needs: sustained R&D and marketing to stay ahead
Integrated Clinical Evidence/KOL Network
Integrated Clinical Evidence/KOL Network is a Stars driver: Veracyte’s steady publication cadence and KOL advocacy — over 350 peer-reviewed studies by 2024 — act as growth flywheels for test adoption, translating guideline nods into market-share gains and supporting consistent uptake across markets.
- Evidence scale: >350 peer-reviewed studies (2024)
- Guideline impact: accelerates market share
- Cross-product leverage: multiplies launch ROI
- Recommendation: sustained investment
Clinical genomics: majority payer coverage, >350 studies, 40-60% treatment change
Veracyte Stars (Afirma GSC, Decipher, Percepta, WTS platform, evidence network) drive high growth via strong clinical evidence, broad payer coverage and expanding TAM; 2024 milestones include majority Medicare/commercial coverage for Afirma, Decipher treatment-change 40–60%, LDCT eligibility ~9M and >350 peer-reviewed studies. Continued R&D, access and integration investment needed to convert to Cash Cows.
| Asset | 2024 metric | Status |
|---|---|---|
| Afirma Thyroid GSC | Majority Medicare/commercial coverage (2024) | Star |
| Decipher | Treatment-change 40–60% (2024) | Star |
| Percepta | LDCT eligible ~9M; nodules in ≤25% screened | Star |
| WTS platform / Evidence | >350 peer-reviewed studies (2024) | Star |
What is included in the product
Detailed Word Document
Concise BCG analysis of Veracyte products, identifying Stars, Cash Cows, Question Marks and Dogs with investment recommendations.
Customizable Excel Spreadsheet
One-page Veracyte BCG Matrix highlighting pain points per unit for quick strategy decisions
Cash Cows
Prosigna (Breast) IVD Kit
Prosigna (Breast) is a recognized PAM50 assay with established channel access and steady demand in a mature breast oncology market where ACS estimated 297,790 new invasive breast cancer cases in the US in 2024, supporting predictable test volumes.
The category is competitive but stable with reproducible reimbursement pathways and low incremental promo needs; focus shifts to operational efficiency and distributor leverage to protect margins.
The product is a reliable cash generator for Veracyte, enabling reinvestment while sustaining quality, clinical support, and lab service standards.
Decipher Prostate (Established Accounts)
In incumbent sites, Decipher Prostate volumes are predictable and workflows are locked in, with 2024 site-level utilization showing steady repeat testing. Margins benefit from scale and minimal incremental selling, driving strong cash generation despite modest unit growth. Focus on optimizing operations and targeted account expansion at the edges to lift returns and extend share within established accounts.
Thyroid Testing Services (Core Benign Rule‑Out Stream)
Afirma-based thyroid samples deliver dependable throughput, processing roughly 60,000 samples in 2024 and underpinning steady revenue. Market growth is slower in mature regions, where Afirma holds about 55% share, but unit economics remain strong. Limited incremental marketing spend is required to sustain this position. Targeted investments in lab automation and workflow can widen cash contribution by an estimated 3–5 percentage points.
Partnered IVD Distribution Revenues
Partnered IVD distribution revenues from existing kit placements and channel partners deliver recurring, lower-touch cash flow for Veracyte, with category growth modest while utilization remains steady; focus should be on service quality and tight cost control rather than heavy promotion to protect margins and predictability.
- Recurring, lower-touch revenue
- Modest category growth, steady utilization
- Prioritize service quality and cost control
- Reliable funding source for pipeline investments
Clinical Operations at Scale (Central Lab)
Clinical Operations at Scale (Central Lab) is a cash cow: high fixed costs are absorbed by mature tests, with 2024 throughput up ~15% and contribution margins near 70%, making each marginal test highly profitable. Growth is low but cash conversion remained attractive in 2024, with operating cash flow covering capex and working capital. Continue automation and throughput gains to further milk incremental profit.
- 2024 throughput +15%
- Contribution margin ≈70%
- Low revenue growth, high cash conversion
- Priority: automation and yield improvements
Breast cases 297,790; thyroid ~60,000; lab +15% recurring cash
Prosigna benefits from 2024 US breast incidence ~297,790 supporting steady volumes; Decipher Prostate shows locked-in site workflows and predictable repeat testing. Afirma processed ~60,000 samples in 2024 with ~55% share in mature regions. Central lab throughput +15% in 2024 with ~70% contribution margin, all delivering strong recurring cash flow.
| Product | 2024 KPI | Role |
|---|---|---|
| Prosigna | US cases 297,790 | Steady cash |
| Afirma | ~60,000 samples; 55% share | Reliable revenue |
| Central Lab | Throughput +15%; ≈70% margin | High cash conversion |
Preview = Final Product
Veracyte BCG Matrix
The file you’re previewing is the exact BCG Matrix report you’ll receive after purchase—no watermarks, no sample text, just the finished, fully formatted document. It’s been crafted for clarity and strategic use, ready to download, edit, print, or present. Purchase delivers the same file straight to your inbox—no surprises, no extra edits needed.
